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Introduction
Reversible posterior leukoencephalopathy syndrome (RPLS), also known as posterior 
reversible encephalopathy syndrome, was a term first used by Hinchey et al1 in 1996 
to describe a distinct clinico-radiological entity comprising headache, seizures, visual 
disturbance, and altered mental function associated with symmetrical posterior cerebral 
white matter oedema. The syndrome is thought to be reversible in the majority of the cases 
upon control of hypertension and the underlying precipitating factor.1,2 Imaging of the 
brain typically shows symmetrical hemispheric oedema predominantly in bilateral parieto-
occipital regions.3 Other cortical regions, as well as the cerebellum, brainstem and basal 
ganglia, may also be affected.4 The pathophysiology of RPLS is not fully understood, but is 
believed to be related to failure of cerebral auto-regulation leading to vasogenic oedema.1,3-6 
It has been associated with a number of clinical conditions including hypertension, 
eclampsia and immunosuppressive therapy.1 While there is increasing awareness of RPLS 
and high-dose multi-drug cancer therapy, we reviewed its clinical presentation, initial and 
follow-up radiological features as well as the neurological outcome in Chinese paediatric 
patients who developed this syndrome while receiving cytotoxic chemotherapy for 
cancers.
Methods
All children with cancers who received chemotherapy and diagnosed to have RPLS between 
1 January 1998 and 31 December 2008 at Tuen Mun Hospital, Hong Kong were included. 
They were identified using Clinical Management System (CMS), out-patient records and 
the Clinical Development and Reporting System (CDARS). The latter used a text-retrieval 
system that searches the final diagnosis in the electronic clinic notes for coded text. We 
started recruiting patients by using both CMS and CDARS to identify all patients admitted 
to the paediatric unit with the following ICD-9 codes: 323.9 for leukoencephalopathy, 
780.32 for convulsion, 780.09 for unconsciousness/loss of consciousness, 369.9 for drug-
related visual impairment. We then narrowed down our search by only recruiting those 
patients who had previous admissions with the above codes and were admitted under 
the subspecialty code PHO which stands for paediatric haematology-oncology. Then the 
case summary of each patient was reviewed and cases were included if the corresponding 
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從1998年至2008年期間，於一所分區醫院內因癌症接受化療並確診患
有可逆性後部白質腦病綜合徵的五名華籍小童，本研究對他們的臨床
放射症狀及腦神經表現作病例回顧。五名小童分別為三男二女，平均
年齡7歲。其中四人有急性淋巴細胞性白血病，一人有中樞神經系統生
殖細胞瘤。他們的症狀包括癲癇發作（100%）、意識障礙（100%）、
頭痛（40%）及視覺障礙（60%）；病發時平均收縮壓為158	mm	Hg。
約有八成患者出現可逆性後部白質腦病綜合徵的典型影像特徵。所有
患者在急性期過後完全康復，只有一位患者隨後有癲癇發作。兩名患
者最終因難治性惡性疾病死亡。其餘兩名患者的神經系統在六年的隨
訪期內仍然保持正常。本文是對華籍小兒癌症患者的可逆性後部白質
腦病綜合徵的首個病例回顧，患者的臨床放射症狀及腦神經表現與西
方文獻相若。及時有效的治療對診治此症相當重要。此外，由於中央
神經系統的破壞可以是永久性，因此長期的隨訪是需要的。
因化療引致的可逆性後部白質腦病綜合徵：
五名華籍小兒患者的病例回顧
germ cell tumour. Three of those with ALL developed 
RPLS while receiving re-induction chemotherapy 
according to the I-BFM 2002 protocol. Re-induction 
chemotherapy (protocol II) was given approximately 
5 months after diagnosis and lasted 7 weeks. It 
consisted of dexamethasone, vincristine, doxorubicin 
and L-asparaginase in protocol IIa; and cytarabine, 
cyclophosphamide and 6-thioguanine in protocol 
IIb. These three patients developed symptoms 
during the protocol IIa phase of their chemotherapy. 
The remaining patient with ALL was receiving 
consolidation chemotherapy (High Risk Block 1) 
according to the I-BFM 2002 protocol, which lasted 11 
days and consisted of dexamethasone, vincristine, L-
asparaginase, methotrexate and cytarabine, and was 
given at week 12 after the diagnosis. The patient with 
the pituitary germ cell tumour was treated with BEP 
(cisplatin, etoposide and bleomycin). 
 Clinical seizures occurred in all five patients; in 
two of them the onset was focal. Altered mental state 
was also present in all five patients, two of whom had 
headaches and three had visual disturbance. The 
mean peak systolic blood pressure at presentation 
was 158 mm Hg (range, 148-165 mm Hg).
 Magnetic resonance imaging (MRI) of the brain 
was performed for all the patients within 1 week of 
presentation. Typical RPLS findings were found in four 
of the cases, and consisted of bilateral symmetrical 
grey matter and subcortical white matter lesions in 
cerebral hemispheres, in particular at parietal and 
occipital lobes (Fig a), and one had abnormal T2-
weighted hyperintense bilateral frontal lobe white 
matter lesions (Table). 
 All of the patients had a complete clinical 
clinical picture matched the definition of RPLS.
 The demographic data, underlying malignant 
diseases, chemotherapeutic agents used, presenting 
symptoms, blood pressure values, initial and follow-
up electroencephalograms and neuroimaging 
findings, and neurological outcomes were collected 
for each patient. 
Results
We identified five episodes of RPLS in 5 patients 
(3 males) with a mean age of 7 (range, 4-11) years 
at presentation (Table). Four patients had acute 
lymphoblastic leukaemia (ALL) and one had a pituitary 
* ALL denotes acute lymphoblastic leukaemia, AMF altered mental function, BP blood pressure, EEG electroencephalogram, HA headache, MRI magnetic resonance 
imaging, NA not available, VD visual disturbance
TABLE. Case summary of patients with reversible posterior leukoencephalopathy syndrome*
Patient No. Sex/age 
(years)
Cancer type Chemotherapy Clinical symptoms BP (mm Hg) Time of resolution of clinical 
features 
EEG findings at presentation MRI findings at presentation MRI findings within 4 weeks Long-term sequelae
1 F/7 Pituitary germ 
cell tumour
Cisplatin, etoposide, 
bleomycin
Seizure, HA, VD, AMF 158/100 Seizure ceased: 1 hour 
Normal vision: 6 hours 
Full consciousness: 2 hours 
Normal BP: 2 days
Post-ictal changes and some 
intermittent slow waves
Bilateral symmetrical cortical and 
subcortical white matter oedema at 
parietal and occipital lobes 
Complete resolution Died of relapsed brain tumour
2 M/4 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, HA, AMF, 
hyporeflexia
148/90 Seizure ceased: 5 min 
Full consciousness: 2 hours 
Normal BP: 1 day
Left posterior sharp slow waves Bilateral symmetrical cortical and 
subcortical white matter oedema at 
bilateral parietal and occipital lobes
Complete resolution None
3 M/11 ALL Dexamethasone, 
vincristine, methotrexate, 
cytarabine, L-asparaginase
Seizure, AMF, VD 165/101 Seizure ceased: 10 min 
Normal vision: 2 days 
Full consciousness: 3 days 
Normal BP: 3 days
No epileptiform discharge Extensive bilateral symmetrical cortical 
and subcortical white matter oedema 
in both cerebral hemispheres
Residual abnormal T2-weighted 
hyperintense subcortical white matter 
lesions at bilateral occipital lobes
Died of refractory leukaemia
4 F/8 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, AMF, 
hyporeflexia
165/108 Seizure ceased: 30 min 
Full consciousness: 3 hours 
Normal BP: 3 days
NA Bilateral symmetrical white matter 
oedema at frontal lobe
Complete resolution Epilepsy 
(MRI brain 7 years later: right 
mesial temporal sclerosis)
5 M/4 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, AMF, VD 155/106 Seizure ceased: 20 min 
Normal vision: 3 days 
Full consciousness: 1 day 
Normal BP: 2 days
Posterior sharp slow waves Bilateral symmetrical white 
matter oedema at parietal and 
occipitotemporal lobes
Small focal infarcts at right occipital lobe None
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recovery upon receiving antihypertensive therapy, 
anti-epileptic therapy, and discontinuation of the 
possible offending drugs. Follow-up MRI of the 
brain was performed within 1 month of presentation. 
Complete resolution of the grey matter and 
subcortical white matter lesions (Fig b) was observed 
in three patients (Nos. 1, 2, and 4). While residual 
abnormal T2-weighted hyperintense signal changes 
were noted in patients 3 and 5, who had no further 
follow-up MRIs; patient 3 died shortly afterwards due 
to refractory disease, and patient 5 had no clinical 
neurological deficit. 
 No patients had recurrence of RPLS, despite 
subsequent continuation of chemotherapy. However, 
patient 4 went on to develop refractory epilepsy; an 
MRI of the brain performed 7 years later revealed 
right mesial temporal sclerosis. Two patients (Nos. 
1 and 3) later died of refractory malignant disease. 
Patient No. Sex/age 
(years)
Cancer type Chemotherapy Clinical symptoms BP (mm Hg) Time of resolution of clinical 
features 
EEG findings at presentation MRI findings at presentation MRI findings within 4 weeks Long-term sequelae
1 F/7 Pituitary germ 
cell tumour
Cisplatin, etoposide, 
bleomycin
Seizure, HA, VD, AMF 158/100 Seizure ceased: 1 hour 
Normal vision: 6 hours 
Full consciousness: 2 hours 
Normal BP: 2 days
Post-ictal changes and some 
intermittent slow waves
Bilateral symmetrical cortical and 
subcortical white matter oedema at 
parietal and occipital lobes 
Complete resolution Died of relapsed brain tumour
2 M/4 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, HA, AMF, 
hyporeflexia
148/90 Seizure ceased: 5 min 
Full consciousness: 2 hours 
Normal BP: 1 day
Left posterior sharp slow waves Bilateral symmetrical cortical and 
subcortical white matter oedema at 
bilateral parietal and occipital lobes
Complete resolution None
3 M/11 ALL Dexamethasone, 
vincristine, methotrexate, 
cytarabine, L-asparaginase
Seizure, AMF, VD 165/101 Seizure ceased: 10 min 
Normal vision: 2 days 
Full consciousness: 3 days 
Normal BP: 3 days
No epileptiform discharge Extensive bilateral symmetrical cortical 
and subcortical white matter oedema 
in both cerebral hemispheres
Residual abnormal T2-weighted 
hyperintense subcortical white matter 
lesions at bilateral occipital lobes
Died of refractory leukaemia
4 F/8 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, AMF, 
hyporeflexia
165/108 Seizure ceased: 30 min 
Full consciousness: 3 hours 
Normal BP: 3 days
NA Bilateral symmetrical white matter 
oedema at frontal lobe
Complete resolution Epilepsy 
(MRI brain 7 years later: right 
mesial temporal sclerosis)
5 M/4 ALL Dexamethasone, 
doxorubicin, vincristine,  
L-asparaginase
Seizure, AMF, VD 155/106 Seizure ceased: 20 min 
Normal vision: 3 days 
Full consciousness: 1 day 
Normal BP: 2 days
Posterior sharp slow waves Bilateral symmetrical white 
matter oedema at parietal and 
occipitotemporal lobes
Small focal infarcts at right occipital lobe None
FIG. Magnetic resonance images of the brain in patient No. 2 
(a) At presentation: coronal T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence showing bilateral cortical and sub-
cortical white matter oedema at parieto-occipital lobes, and (b) at follow-up: coronal T2-weighted FLAIR sequence showing complete 
resolution of the white matter oedema
(a) (b)
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Patients 2 and 5 remained neurologically stable after 
a mean follow-up of 6 years.
Discussion
Reversible posterior leukoencephalopathy 
syndrome was first described by Hinchey et al1 
in 1996 in 15 patients, of whom seven were on 
immunosuppressive therapy. Over the years, RPLS 
has been known by other names including: posterior 
reversible encephalopathy syndrome, reversible 
occipital-parietal encephalopathy,7 posterior 
leukoencephalopathy syndrome, hyperperfusion 
encephalopathy, reversible encephalopathy, 
occipital-parietal encephalopathy, and reversible 
posterior cerebral oedema syndrome.8 Reversible 
posterior leukoencephalopathy syndrome is 
characterised by subacute or acute onset of headache, 
altered consciousness and behaviour, and visual 
disturbance (ranging from blurred vision to total 
cortical blindness); seizures are common and usually 
herald onset of the syndrome.1,5,9 In our case review, 
three of the five cases had such classical symptoms, 
which were similar to previous descriptions in the 
paediatric literature.6 Focal neurological deficits 
are uncommon1,8 as agreed in our cases. Typical 
radiological features are bilateral symmetrical 
predominant white matter oedema affecting 
parietal and occipital lobes, frontal lobes, inferior 
temporo-occipital junctions and the cerebellum, 
and resemble brain watershed zones.1,9 The cortex is 
involved to varying degrees. Partial, asymmetric, or 
mixed patterns may be encountered, which can be a 
diagnostic challenge. Magnetic resonance diffusion-
weighted imaging is used to offer a prognosis, as focal 
areas of restricted diffusion indicate infarction and 
hence signifying an adverse outcome.10 The majority 
of the patients show complete or near-complete 
resolution of clinical and radiological abnormalities 
within days to weeks.1,4 In a case series involving 
36 adults, 66% of the patients showed complete 
resolution of the imaging abnormalities, occurring 
as early as 5 days after the onset.4 Only three of our 
patients showed complete radiological resolution 
in their follow-up MRIs 4 weeks later, while two 
showed residual abnormalities without any obvious 
neurological deficit. 
 The true incidence of RPLS is unknown, but 
it affects age-groups ranging from 2 to 78 years.4,9 
It is commonly associated with hypertensive 
encephalopathy, eclampsia, renal failure, and the use 
of immunosuppressive therapy.1,5 In our paediatric 
oncology patients, we only focused on RPLS induced 
by chemotherapy. So far, Morris et al11 have described 
the largest paediatric series in cancer children and 
included 11 children. 
 The pathophysiology of RPLS still remains 
unclear. Sudden elevations in blood pressure 
exceeding the auto-regulatory capacity of the 
brain and direct or indirect cytotoxic effects 
of immunosuppressive agents on the vascular 
endothelium have both been implicated. Both 
lead to a breakdown of the blood-brain barrier 
with transudation of fluid and haemorrhage. The 
preferential involvement of the parietal and occipital 
lobes is believed to be related to the relative sparse 
sympathetic innervation of the posterior circulation.1 
Whatever the aetiology, whether multi-factorial or 
not, the key feature seems to be vascular endothelial 
damage. Predilection of the white matter rather than 
grey matter has been hypothesised due to the tightly 
packed cortex as compared to white matter, which 
results in water accumulation.
 Another more recently proposed 
pathophysiology involves cortical spreading 
depression (CSD) which is a phenomenon similar 
to that occurring in migraines. Sánchez-Carpintero 
et al12 performed single-photon emission computed 
tomography scans on three children who developed 
RPLS while receiving treatment for osteosarcoma, and 
demonstrated hypoperfusion of the parietal-occipital 
regions of the brain. Although CSD is a phenomenon 
which is as yet not completely understood, it is 
known that hypomagnesaemia is strongly associated 
with its development. 
 A review of paediatric oncology literature 
showed an increasing awareness of RPLS as a 
complication of cancer treatment.5-7,12-14 No single 
chemotherapeutic agent or therapeutic regimen has 
been identified as causal and consistently associated. 
Implicated drugs include cisplatin,15 cyclosporine,16 
or gemcitabine17 as well as combinations of 
doxorubicin, L-asparaginase, cyclophosphamide, 
vincristine, corticosteroids, ifosfamide, etoposide 
and cytarabine.5,13,14 One of our patients (patient 1) 
received cisplatin and etoposide. Three patients 
received a combination of dexamethasone, 
vincristine, L-asparaginase and doxorubicin. It will 
be difficult to identify which agent is the culprit. An 
important observation was that four of our patients 
received high doses of steroids during the re-
induction and induction phase for ALL. High-dose 
steroids may trigger RPLS directly or indirectly by 
contributing to steroid-induced hypertension. 
 Once RPLS has been diagnosed, it is essential to 
provide supportive (including intensive care unit) care 
and aggressive treatment of seizures, hypertension, 
and electrolyte imbalances. Hypertension is a 
common feature in most reported cases complicating 
cytotoxic chemotherapy.13,15,18 In contrast to malignant 
hypertension-induced encephalopathy, patients 
with RPLS usually present with only moderately 
high blood pressure, representing a significant 
increase above baseline values. In our series, the 
mean systolic blood pressure at presentation was 158 
mm Hg (range, 148-165 mm Hg). Antihypertensive 
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